CTMX241115C12000
- 0.00
- 0.000.00%
CytomX Newsroom
H.C. Wainwright Sticks to Their Hold Rating for CytomX Therapeutics (CTMX)
Express News | CytomX Therapeutics Announces First Patient Dosed With Cx-801, a Dually-Masked Interferon-Alpha 2B Probody®, in a Phase 1 Study in Patients With Solid Tumors
CytomX Therapeutics Announces First Patient Dosed With CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients With Solid Tumors
CytomX Therapeutics to Present at Upcoming September Investor Conferences
Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and CytomX Therapeutics (CTMX)
HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics
CytomX Therapeutics Analyst Ratings
H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating
H.C. Wainwright analyst Mitchell Kapoor maintains $CytomX(CTMX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 39.7% and a total average return of -10.8% over
CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
CytomX Therapeutics Files $250M Mixed Securities Shelf
Express News | CytomX Therapeutics - Sales Agreement Prospectus Covering Offering of up to $58.3 Mln Common Stock That May Be Issued From Time to Time
Express News | CytomX Therapeutics Inc Files for Mixed Shelf of up to $250 Mln – SEC Filing
Earnings Call Summary | CytomX(CTMX.US) Q2 2024 Earnings Conference
Express News | CytomX Therapeutics Inc : BMO Cuts Target Price to $3.56 From $3.59
CytomX Therapeutics (CTMX) Receives a Buy From Barclays
CytomX | 10-Q: Q2 2024 Earnings Report
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q2 Revenue $25.1M, Vs. Street Est of $20M
CytomX GAAP EPS of -$0.08 Misses by $0.01, Revenue of $25.11M Beats by $5.12M
CytomX Therapeutics 2Q Loss/Shr 8c >CTMX
Express News | CytomX Therapeutics Q2 Net Income USD -6.534 Million